| [1] |
Garces CA, Cance WG. Neoadjuvant chemotherapy of breast cancer[J].Am Surg,2004,70(7):565-569.
|
| [2] |
Mamounes EP, Wang J, Bryant J, et al. Patterns of loco-regional failure(LRF) in patients receiving neoadjuvant chemotherapy (NC):results from NSABP-18[J]. Breast Cancer Res Treat,2003,82 (Supple1):17-23.
|
| [3] |
惠锐,张瑾,范宇. 乳腺癌新辅助化疗后病理缓解的临床意义[J]. 中华医学杂志,2008,88(14),961-964.
|
| [4] |
Colleoni M, Orvieto E, Nolé F, et al. Prediction of response to primary chemotherapy for operable breast cancer[J].Eur J Cancer,1999,35(4):574-579.
|
| [5] |
Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy[J].Breast Cancer Res Treat,2000,59 (2):171-175.
|
| [6] |
Zhang F, Yang Y, Smith T, et a1.Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil,doxorubicin,and cyclophosphamid in patients with breast carcinoma[J]. Cancer,2003,97(7):1758-1765.
|
| [7] |
Taucher S,Rudas M,Mader RM, et al.Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer[J]. Breast Cancer Res Treat,2003,82(3):207-213.
|
| [8] |
Euler U,Tulusan AH. An attempt to identify biological markers predicting response to primary chemotherapy with epirubiein/cyclophosphamid in locally advance breast cancer[C].2003 ASCO Annual Meeting.
|
| [9] |
Pohl G,Rudas M,Taucher S,et a1. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy[J].Breast Cancer Res Treat.2003,78(1):97-103.
|
| [10] |
Davis DW,Buchholz TA,Hess KR,et a1.Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer:early assessment predicts clinical response[J].Clin Cancer Res,2003,9(3):955-960.
|
| [11] |
邵志敏,李俊,吴炅,等. 术前化疗诱导乳腺癌细胞凋亡的临床意义[J].中华肿瘤杂志,2000,22(4):295-300.
|
| [12] |
Chintamani Singhal V,Singh JP,Lyall A, et al. Is drug induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? a prospective clinical study[J]. BMC Cancer,2004,4(1):48-56.
|
| [13] |
Faneyte IF,Schrama JG,Peterse JL,et a1.Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome[J]. Br J Cancer,2003,88(3):406-412.
|
| [14] |
Pusztai L, Krishnamurti S, Perez CJ, et a1. Expression of BAG-1 and Bcl-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer[J]. Cancer Invest,2004,22 (2):248-256.
|
| [15] |
Buchholz TA,Ang KK,Tu X,et al,Epidermal growth factor receptor expression correlates with survival in breast cancer patient treated with doxombicin based neoadjuvant chemotherapy[J].Breast Cancer Res Treat,2003,82 (Supple 1):122-126.
|
| [16] |
Clemons M, Goss P. Estrogen and the risk of breast cancer[J]. N Engl J Med,2001,344(23):276-285.
|
| [17] |
Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors[J]. J Clin Oncol,2006,24(7):1037-1044.
|
| [18] |
Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy[J]. Clin Cancer Res,2005,11 (24 pt 1):8715-8721.
|
| [19] |
Lo SS, Wang HC, Shyr YM, et al. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? [J]. J Surg Oncol,1994,57(2):94-96.
|
| [20] |
Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma[J]. Am Surg,1996,62(2):162-165.
|
| [21] |
Makris A, Powels TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study [J]. Breast Cancer Res Treat,1999,53(1):51-59.
|
| [22] |
Lee SH, Chung MA, Quddus MR. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormonal receptor status in breast cancer [J]. Am J Surg,2003,186(4):384-390.
|
| [23] |
Ayers M,Symmans WF,Stec J,et a1.Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil,doxorubicin,and cyclophosphamide chemotherapy in breast cancer[J]. J Clin Oncol,2004,22(12):2284-2293.
|
| [24] |
Chang JC, Wooten EC, Tsimelzon A, et a1. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet,2003,362(9381):362-369.
|